| News

Polyneuron medication receives orphan drug status in the USA

11.06.2020

The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.

Ruben Herrendorff, CEO Polyneuron Pharmaceuticals

According to a press release, a drug manufactured by Polyneuron Pharmaceuticals AG based in Basel has received orphan drug status from the American health authority, the FDA. This status granted to medicines for use in rare diseases helps pharmaceutical companies to develop drugs for which there is only a very small niche market.

The drug developed by Polyneuron, called PN-1007, was developed to treat the autoimmune disease anti-MAG neuropathy. Over the course of the disease, the peripheral nerves become increasingly damaged, which can lead to physical impairments. There is currently no treatment with marketing authorization for this. PN-1007 neutralizes the autoantibodies responsible for this damage.

PN-1007 was already granted orphan drug status by the European Union back in 2017. Health authorities use this to encourage the development of such drugs through tax breaks and discounted fees, for instance in clinical testing. Additionally, research funds and long-term market exclusivity are guaranteed for ten years in the EU and for seven in the USA.

In a financing round in March this year, Polyneuron secured 22.5 million Swiss francs for its first clinical trial with this active substance.

Dr. Ruben Herrendorff, CEO and Co-Founder of Polyneuron, explains: “Receiving orphan designation in the U.S. provides additional validation to the development of PN-1007 as a treatment for anti-MAG neuropathy.” He goes on to add that data published recently in the Journal of Neurochemistry supports this. “We now look forward to evaluating PN-1007 in patients when our phase I/IIa study in anti-MAG neuropathy starts later in 2020.”

Polyneuron is headquartered at Technologiepark Basel. The company has also received support within the framework of BaseLaunch, the healthcare accelerator of the investment and innovation promotion agency Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Roche tests able to detect Omicron
Basel Area Business & Innovation, Innovation, Invest

Roche tests able to detect Omicron

The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of...

Read More
Hemex banks 7.1 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Hemex banks 7.1 million Swiss francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company...

Read More
EsoCap impresses investors
Basel Area Business & Innovation, Innovation, Invest

EsoCap impresses investors

EsoCap, a biotech company based in Basel, has concluded a successful funding round. The funds from new and existing investors...

Read More
Plug and Play settles in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Plug and Play settles in the Basel Area

Plug and Play is coming to the canton of Basel-Landschaft. The first founding partner of the innovation promoter from Silicon...

Read More
Bachem builds its largest production building
Basel Area Business & Innovation, Innovation, Invest

Bachem builds its largest production building

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of...

Read More
Bottneuro advancing personalized Alzheimer’s therapy
Basel Area Business & Innovation, Innovation, Invest

Bottneuro advancing personalized Alzheimer’s therapy

Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of...

Read More
1 2 3 50

Do you have a question? We'd like to hear from you.